Brief: Oncology firm Silexion To Go Public In $62.5 Mln SPAC Deal

Silexion Therapeutics

22/02/2024 14:34

Feb 22 (Reuters) - Moringa Acquisition Corp  MACA.O :
    * SILEXION, A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOTECHNOLOGY
COMPANY, TO BECOME PUBLICLY TRADED VIA BUSINESS COMBINATION WITH
MORINGA ACQUISITION CORP
    * MORINGA ACQUISITION CORP - BUSINESS COMBINATION PROVIDES
FOR
SILEXION'S PRE-TRANSACTION EQUITY VALUE TO BE $62.5 MILLION
    * MORINGA ACQUISITION CORP - BUSINESS COMBINATION
UNANIMOUSLY
APPROVED BY BOARDS OF DIRECTORS OF SILEXION AND MORINGA
    * MORINGA ACQUISITION CORP - BOARD OF DIRECTORS OF COMBINED
COMPANY WILL CONSIST OF SEVEN MEMBERS, OF WHOM TWO WILL BE
APPOINTED BY MORINGA'S SPONSOR

Source text for Eikon:  ID:nGNXbC78NQ 
Further company coverage:  MACA.O 

 ((Reuters.Briefs@thomsonreuters.com;))